Cypress Capital Management LLC WY continued to hold its position in Abbott Laboratories (NYSE:ABT) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,531 shares of the healthcare product maker’s stock at the end of the second quarter. Cypress Capital Management LLC WY’s holdings in Abbott Laboratories were worth $123,000 as of its most recent SEC filing.

Other institutional investors also recently bought and sold shares of the company. Sanders Morris Harris LLC raised its position in Abbott Laboratories by 0.3% in the second quarter. Sanders Morris Harris LLC now owns 4,986 shares of the healthcare product maker’s stock valued at $242,000 after buying an additional 16 shares during the period. Janney Capital Management LLC raised its position in Abbott Laboratories by 0.4% in the first quarter. Janney Capital Management LLC now owns 6,229 shares of the healthcare product maker’s stock valued at $276,000 after buying an additional 26 shares during the period. Alpha Windward LLC raised its position in Abbott Laboratories by 0.6% in the second quarter. Alpha Windward LLC now owns 5,434 shares of the healthcare product maker’s stock valued at $264,000 after buying an additional 30 shares during the period. Johanson Financial Advisors Inc. raised its position in Abbott Laboratories by 0.5% in the second quarter. Johanson Financial Advisors Inc. now owns 7,017 shares of the healthcare product maker’s stock valued at $343,000 after buying an additional 37 shares during the period. Finally, Country Club Trust Company n.a. raised its position in Abbott Laboratories by 0.5% in the second quarter. Country Club Trust Company n.a. now owns 7,320 shares of the healthcare product maker’s stock valued at $356,000 after buying an additional 38 shares during the period. Institutional investors own 70.98% of the company’s stock.

Abbott Laboratories (NYSE:ABT) traded up 1.00% during midday trading on Friday, hitting $48.54. The company had a trading volume of 3,978,902 shares. The company has a market cap of $84.34 billion, a price-to-earnings ratio of 67.98 and a beta of 1.07. Abbott Laboratories has a 12 month low of $37.38 and a 12 month high of $51.13. The firm has a 50-day moving average price of $49.09 and a 200-day moving average price of $45.65.

Abbott Laboratories (NYSE:ABT) last released its quarterly earnings results on Thursday, July 20th. The healthcare product maker reported $0.62 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.60 by $0.02. The firm had revenue of $6.64 billion for the quarter, compared to the consensus estimate of $6.63 billion. Abbott Laboratories had a return on equity of 14.43% and a net margin of 4.96%. The firm’s quarterly revenue was up 24.5% compared to the same quarter last year. During the same quarter last year, the business posted $0.55 EPS. Equities analysts anticipate that Abbott Laboratories will post $2.49 EPS for the current year.

The company also recently declared a quarterly dividend, which will be paid on Tuesday, August 15th. Investors of record on Friday, July 14th will be paid a dividend of $0.265 per share. The ex-dividend date is Wednesday, July 12th. This represents a $1.06 dividend on an annualized basis and a yield of 2.18%. Abbott Laboratories’s dividend payout ratio is presently 149.30%.

COPYRIGHT VIOLATION NOTICE: “Abbott Laboratories (NYSE:ABT) Stake Held by Cypress Capital Management LLC WY” was first posted by Watch List News and is the property of of Watch List News. If you are viewing this piece of content on another domain, it was stolen and reposted in violation of U.S. & international copyright & trademark law. The original version of this piece of content can be accessed at https://www.watchlistnews.com/abbott-laboratories-nyseabt-stake-held-by-cypress-capital-management-llc-wy/1479859.html.

Several equities analysts have issued reports on the company. UBS AG reiterated a “neutral” rating and issued a $41.00 target price on shares of Abbott Laboratories in a research note on Tuesday, April 18th. TheStreet lowered Abbott Laboratories from a “b” rating to a “c+” rating in a research note on Thursday, May 18th. Royal Bank Of Canada reiterated a “buy” rating on shares of Abbott Laboratories in a research note on Monday, May 15th. Jefferies Group LLC cut their target price on Abbott Laboratories from $52.00 to $50.00 and set a “buy” rating on the stock in a research note on Tuesday, April 18th. Finally, Cowen and Company reissued an “outperform” rating and issued a $48.00 price target on shares of Abbott Laboratories in a report on Saturday, April 22nd. Six investment analysts have rated the stock with a hold rating and nine have given a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus target price of $51.93.

In related news, insider Sharon J. Bracken sold 2,000 shares of the firm’s stock in a transaction that occurred on Tuesday, August 1st. The stock was sold at an average price of $49.16, for a total transaction of $98,320.00. Following the transaction, the insider now owns 28,806 shares in the company, valued at approximately $1,416,102.96. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Brian J. Blaser sold 15,000 shares of the firm’s stock in a transaction that occurred on Thursday, July 27th. The stock was sold at an average price of $50.00, for a total value of $750,000.00. Following the transaction, the insider now owns 143,154 shares in the company, valued at approximately $7,157,700. The disclosure for this sale can be found here. Insiders have sold a total of 218,702 shares of company stock worth $10,149,733 in the last 90 days. 0.76% of the stock is currently owned by company insiders.

About Abbott Laboratories

Abbott Laboratories is engaged in the discovery, development, manufacture and sale of a range of healthcare products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. Its Established Pharmaceutical Products include a range of branded generic pharmaceuticals manufactured around the world and marketed and sold outside the United States.

Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT).

Institutional Ownership by Quarter for Abbott Laboratories (NYSE:ABT)

Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with Analyst Ratings Network's FREE daily email newsletter.